Definium Therapeutics, Inc. (DFTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$262.5M
Cash & Equivalents
$42.6M
Quarterly Burn Rate
18 mo
Est. Cash Runway
$6,248M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06941844 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) | PHASE3 | Active Not Recruiting | 149 |
| NCT06741228 | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | PHASE3 | Active Not Recruiting | 214 |
| NCT07592689 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | PHASE3 | Recruiting | 165 |
| NCT07303907 | A Phase 2A Trial of DT402 for Autism Spectrum Disorder | PHASE2 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.